ANAB

51.00

1.35% -0.70

Handel nachbörslich: 51.00

Anaptysbio Inc (ANAB)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$51.70

Offen:

$52.38

24-Stunden-Volumen:

437.40K

Relative Volume:

0.74

Marktkapitalisierung:

$1.52B

Einnahmen:

$232.39M

Nettoeinkommen (Verlust:

$-26.79M

KGV:

-47.20

EPS:

-1.0804

Netto-Cashflow:

$4.41M

1W Leistung:

-7.61%

1M Leistung:

-12.63%

6M Leistung:

-22.01%

1J Leistung:

+131.40%

1-Tages-Spanne:

$50.80

$52.38

1-Wochen-Bereich:

$49.45

$56.04

52-Wochen-Spanne:

$20.79

$73.30

Anaptysbio Inc Stock (ANAB) Company Profile

Firmenname

Anaptysbio Inc

Sektor

Healthcare (1067)

Branche

Biotechnology (595)

Telefon

858-362-6295

Adresse

10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA

Mitarbeiter

104

Twitter

@anaptysbio

Nächster Verdiensttermin

2026-11-03

Neueste SEC-Einreichungen

ANAB's Discussions on Twitter

Compare ANAB vs VRTX, REGN, MRNA, ARGX, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ANAB Anaptysbio Inc	51.00	1.52B	232.39M	-26.79M	4.41M	-1.0804
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-07	Fortgesetzt	UBS	Buy
2025-10-13	Eingeleitet	Barclays	Overweight
2025-06-04	Hochstufung	H.C. Wainwright	Neutral → Buy
2025-02-04	Eingeleitet	Wolfe Research	Outperform
2024-12-11	Herabstufung	H.C. Wainwright	Buy → Neutral
2024-12-02	Herabstufung	BTIG Research	Buy → Neutral
2024-07-22	Eingeleitet	H.C. Wainwright	Buy
2024-07-19	Hochstufung	JP Morgan	Neutral → Overweight
2024-04-16	Eingeleitet	Leerink Partners	Outperform
2024-04-11	Eingeleitet	Wells Fargo	Overweight
2024-03-12	Hochstufung	Wedbush	Neutral → Outperform
2024-02-26	Eingeleitet	BTIG Research	Buy
2024-02-21	Eingeleitet	Stifel	Buy
2024-02-16	Eingeleitet	Piper Sandler	Overweight
2023-05-22	Hochstufung	JP Morgan	Underweight → Neutral
2023-05-18	Eingeleitet	TD Cowen	Outperform
2023-01-06	Herabstufung	Raymond James	Outperform → Mkt Perform
2022-11-01	Hochstufung	Guggenheim	Neutral → Buy
2022-09-19	Fortgesetzt	H.C. Wainwright	Buy
2022-09-13	Herabstufung	Truist	Buy → Hold
2022-09-01	Eingeleitet	Raymond James	Outperform
2022-03-22	Herabstufung	Guggenheim	Buy → Neutral
2021-06-22	Eingeleitet	H.C. Wainwright	Buy
2021-05-21	Eingeleitet	UBS	Neutral
2021-03-16	Hochstufung	Truist	Hold → Buy
2021-03-09	Herabstufung	Wedbush	Outperform → Neutral
2021-03-08	Herabstufung	JP Morgan	Overweight → Underweight
2021-02-11	Hochstufung	JP Morgan	Underweight → Overweight
2020-10-27	Hochstufung	Wedbush	Neutral → Outperform
2020-10-14	Hochstufung	Guggenheim	Neutral → Buy
2019-11-08	Herabstufung	JP Morgan	Overweight → Underweight
2019-11-08	Herabstufung	Jefferies	Buy → Hold
2019-11-08	Herabstufung	SunTrust	Buy → Hold
2019-11-08	Herabstufung	Wedbush	Outperform → Neutral
2019-06-21	Herabstufung	Credit Suisse	Outperform → Neutral
2019-06-21	Herabstufung	Stifel	Buy → Hold
2018-12-20	Eingeleitet	H.C. Wainwright	Buy
2018-11-21	Eingeleitet	JP Morgan	Overweight
2018-07-19	Eingeleitet	Credit Suisse	Outperform
2018-04-04	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2018-03-27	Bestätigt	Stifel	Buy
2018-03-06	Bestätigt	Stifel	Buy
2018-02-15	Bestätigt	SunTrust	Buy
2018-01-23	Bestätigt	Credit Suisse	Outperform
2017-11-15	Eingeleitet	SunTrust	Buy
2017-11-09	Eingeleitet	Jefferies	Buy
2017-10-11	Bestätigt	RBC Capital Mkts	Outperform
2017-09-15	Eingeleitet	RBC Capital Mkts	Outperform

Alle ansehen

Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten

10:11 AM

AnaptysBio (ANAB) Is Down 7.6% After Tax-Driven Earnings Surge Masks Underlying Cash Performance - Yahoo Finance

10:11 AM

01:14 AM

AnaptysBio (NASDAQ:ANAB) Stock Bumped Up to Buy by Wall Street Zen - MarketBeat

01:14 AM

Sep 25, 2026

AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns? - Insider Monkey

Sep 25, 2026

How Return To Profit Will Impact AnaptysBio (ANAB) Investors - simplywall.st

Sep 25, 2026

Sep 24, 2026

ANAB Reiterated by HC Wainwright & Co. -- Price Target Maintained at $95 - GuruFocus

Sep 24, 2026

Q3 Earnings Estimate for AnaptysBio Issued By HC Wainwright - MarketBeat

Sep 24, 2026

Sep 23, 2026

ANAB Maintained by Leerink Partners -- Price Target Lowered to $81 - GuruFocus

Sep 23, 2026

Leerink Partners Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat

Sep 23, 2026

Leerink Partners maintains Outperform rating on AnaptysBio, $81 price target - TradingView

Sep 23, 2026

AnaptysBio (ANAB) Flags Positive AZUR 1 Data With Approval And Legal Timelines - simplywall.st

Sep 23, 2026

Bank of America Corp DE Makes New $28.20 Million Investment in AnaptysBio, Inc. $ANAB - MarketBeat

Sep 23, 2026

AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Sep 23, 2026

Sep 22, 2026

AnaptysBio earnings analysis: questions answered and next catalysts - Investing.com

Sep 22, 2026

AnaptysBio (NASDAQ:ANAB) Shares Down 6.2%What's Next? - MarketBeat

Sep 22, 2026

AnaptysBio, Inc. (0HFQ.L) latest press releases and corporate news - Yahoo Finance UK

Sep 22, 2026